Regulatory FDA places clinical hold on Regenxbio’s RGX-121 in MPS II trial Pharmaceutical TechnologyREGENXBIO has reported that the US FDA has placed a clinical hold on its investigational gene therapy, RGX-121, developed for the treatment of MPS II.Rare DiseaseRead full story pharminent August 25, 2026 (Last updated: August 25, 2026) Pharmaceutical Technology REGENXBIO has reported that the US FDA has placed a clinical hold on its investigational gene therapy, RGX-121, developed for the treatment of MPS II. Rare Disease Read full story Post navigation Previous: Genentech Licenses Hanmi’s Muscle-Sparing Obesity Drug in Deal Worth Up to $2.3 BillionNext: FDA greenlights Roche’s biomarker blood test for Alzheimer’s Related Stories Regulatory FDA greenlights Roche’s biomarker blood test for Alzheimer’s pharminent August 25, 2026 Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026
